Chair, Cancer Center Directors

Raymond J. Hohl, MD, PhD, is director of the Penn State Cancer Institute, professor of medicine and pharmacology at the Penn State College of Medicine, Penn State University, and holds the university professorship in medicine. Dr. Hohl is a medical oncologist, hematologist, and clinical pharmacologist and has broad experience as a clinical and translational researcher. Dr. Hohl began his career at the University of Iowa College of Medicine in 1991. He served in a variety of leadership roles during his tenure at the University of Iowa, including director of the division of hematology, oncology and blood and marrow transplantation at the Roy J. and Lucille A. Carver College of Medicine; director of the fellowship program, division of hematology, oncology and blood and marrow transplantation; associate director for clinical research and associate director for clinical translational research at the Holden Comprehensive Cancer Center; and associate chair in the department of internal medicine. Dr. Hohl was named director of Penn State Cancer Institute in 2013.

Chair, Big Ten Cancer Research Consortium Foundation

Raphael E. Pollock, MD, PhD, is director of the Ohio State University Comprehensive Cancer Center and holds the Klotz Chair in Cancer Research. He is also a member of the Translational Therapeutics Program at the OSUCCC – James, where his research focuses on the molecular drivers underlying soft tissue sarcoma, a cancer of connective tissues that occurs throughout the body. Dr. Pollock has authored or co-authored more than 400 original research and review articles as well as 21 books. He has shared his work in over 300 national and international presentations and visiting professorships involving professional audiences in 50 countries worldwide.

Chief Scientific Officer

Monika Joshi, MD, MRCP, is a professor in the Division of Hematology-Oncology in Department of Medicine at the Penn State Cancer Institute (PSCI). She serves as disease team co-leader for the genitourinary diseases group at the PSCI and as medical director for the PSCI Clinical Trials Office. Her clinical and research interests lie primarily in the field of genitourinary tumors, particularly in the field of immunotherapy and targeted therapy. She has an interest in developing clinical trials with novel immunotherapeutic combinations and identifying predictive and prognostic biomarkers. Dr. Joshi has been active in the Big Ten CRC since the consortium’s founding in 2013. In addition to leading multiple Big Ten CRC studies, she served on the Big Ten CRC Steering Committee and as a co-chair the Genitourinary Clinical Trial Working Group.

Steering Committee

The Big Ten CRC Steering Committee is composed of one researcher from each member institution. The Steering Committee meets on a regular basis to review activities of the consortium and decide matters of policy. The Steering Committee determines the criteria for approving concepts for development with the Big Ten CRC.